Gilead Sciences filed its required 13F reports with the Securities and Exchange Commission on June 22, 2026.
1 report, 1 independent
Updated Jun 22
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Gilead Sciences filed its required 13F reports with the Securities and Exchange Commission on June 22, 2026.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Gilead Sciences
American company
- Required regulatory filings regarding institutional holdings were made by Gilead Sciences, Inc. with the Securities and Exchange Commission on June 11, 2026.
- A pilot program is underway involving the federal government, Benue State, and Gilead Sciences, with the state participating in the drug supply management.
-
Securities and Exchange Commission
government agency of the Philippines
Related events
- Merck KGaA filed required 13F reports with the Securities and Exchange Commission regarding institutional holdings on June 15, 2026.
- Gilead Sciences acquired Arcellx and presented priorities at a Wells Fargo conference, while also discussing submissions with the FDA and CDC.
- LiveRamp filed its required 13F reports with the Securities and Exchange Commission.
- 13F filings were submitted to the SEC, mandating disclosure of institutional holdings for the Vanguard Dividend Appreciation ETF.